Rohit Loomba

Liver doctor/Professor of Medicine/clinical trial design Phase 1-4/inventor/drug developer/life's goal to find a cure for liver fibrosis & NASH.

[Uma Mahadevan @UmaMahadevanIBD]

GUILD Conference brings together experts in IBD, Hepatology, EoE, Obesity and many other GI Disciplines. Join us in Puerto Rico or Maui in 2027 for an intimate, high impact course. APP and GI Fellow Scholarships available! Register here: https://t.co/Czle1Ex28Y

[UC San Diego Health @UCSDHealth]

Personalized #CancerCare is changing outcomes. A study led by Jason Sicklick, MD, #UCSDHealth, found that matching treatments to a patient’s tumor #DNA can improve response and survival, bringing us closer to truly individualized cancer care. https://t.co/FZFpSbZHqb @UCSDCancer

[roypounder.apt @APandT]

Read via https://t.co/CDkoEl5Xb9 "Systematic Review: Inclusion of Patients With Difficult-to-Treat Inflammatory Bowel Disease in Randomized Controlled Trials of Advanced Therapies"
#GItwitter #IBD

[Liver Coalition @LiverCoalition]

Thank you, @MadrigalPharma , for sponsoring #MASHAcrossAmerica and for including Chula Vista as a stop on your national tour that gives folks the chance to Meet the Liver. Special shout‑out to campaign partners: @liverUSA, @GlobalLiver, and Liver Education Advocates.

[roypounder.apt @APandT]

"Revisiting Ferritin-IgG Score to Predict Complete Biochemical Response in Autoimmune Hepatitis" is available to read open access via https://t.co/S9WLgAYJiJ
#livertwitter #AIH

[roypounder.apt @APandT]

"Meta-Analysis: The Placebo Response in Modern Treatments for Cholestatic Pruritus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" - read via https://t.co/Nw3VsVbJ3I
#livertwitter #metanalysis #pruritus

[MedPage Today @medpagetoday]

A quarter of patients with cirrhosis from MASLD presented before the age of 50 and had distinct features, including inherited genetic risk factors and type 2 diabetes, according to data from a prospective multicenter study. @DrLoomba
https://t.co/7A8fqBZFmM

[Yehuda Handelsman MD FACP, FNLA, FASPC, FAHA, MACE @YHandelsmanMD]

We are ecstatic to announce our upcoming session, "Contemporary Metabolism – Fat, Brain, & Liver," at the 24th WCIRDC this December! We have a fantastic lineup of experts joining us for this discussion.

TODAY is the last day to secure #Discounted rates at https://t.co/weHQoIrITe

[Rohit Loomba @DrLoomba]

This is an important paper defining younger-onset MASLD cirrhosis and how to identify those patients @AASLDtweets @BavenoCoop @EASLnews @AnandVKulkarni2 @MASLDResearch @MadamSurgeonMD

[UC San Diego Health @UCSDHealth]

Fatty liver disease isn't just affecting older adults. A new @UCSanDiego study found that younger adults who develop cirrhosis have a unique combination of genetic and metabolic risk factors, including type 2 diabetes. @DrLoomba https://t.co/Zpv3Y4ULkL

[Rohit Loomba @DrLoomba]

What's the definition of younger-onset MASLD cirrhosis?
Cirrhosis at < 50 years @AASLDtweets Risk Factors and Definition of Younger-Onset Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Cirrhosis - Clinical Gastroenterology and Hepatology https://t.co/307slHfpPj

[roypounder.apt @APandT]

1st October 2026 issue available to view via https://t.co/NWqkWBBuIm

#GItwitter #livertwitter #MASLD #coeliac #AIH #HCC #EoE #pancreas #ulcerativecolitis #IBD

[Rohit Loomba @DrLoomba]

@NYULH_GastroHep @BilalMohammadMD @AasmaShaukatMD @MarkPochapin @BredellaMD @CTSINYULH @NYULH_DeptofMed Congratulations @AasmaShaukatMD - very well deserved!

[Rohit Loomba @DrLoomba]

@Rajan___Singh @NIH @NIDDKgov @karagm2009 @IBS_Maastricht @mgrover_gi @BMoshiree @LindaNguyenMD @NehaSantucciMD @kaltschmidt_lab @KashyapPurna @BeyderLab @SSrinivasanMD Congratulations Rajan!

[roypounder.apt @APandT]

Read via https://t.co/HcfRsb5ywB "Risk of Coeliac Disease After Immune Checkpoint Inhibitor Exposure in Patients With Cancer"
#GItwitter #coeliacdisease #ICIs

[roypounder.apt @APandT]

Read "Long-Term Major Adverse Liver Outcomes and Oncological Outcomes Across Steatotic Liver Disease Subtypes Classified Using the MetALD-ALD Prediction Index" just published online at https://t.co/GQ2D7faYVX
#livertwitter #MetALD

[Rohit Loomba @DrLoomba]

Our collaborative study on Rx response in MASH in @HEP_Journal @MASLDResearch @DrHuangDQ @UCSD_GI @pattymaysent @VWSWong
Clinical utility of a 30% reduction in VCTE-derived liver stiffness measurement for identifying histologic improvement in MASH https://t.co/1YhkfKpkBB

[Rohit Loomba @DrLoomba]

@JenLaiLiverDoc Thanks for highlighting our paper @JenLaiLiverDoc ! Couldn’t agree more with you 🙏 !

[MASLD Research Center @MASLDResearch]

Please to share our article co-authored by @DrLoomba, ALG-055009 shows promise in reducing liver fat and improving lipid profiles in non-cirrhotic MASH patients with a favorable safety profile!
https://t.co/vBuje286Na
@UCSD_GI @LancetGastroHep

[UCSD Gastroenterology @UCSD_GI]

Join us on Sep 16 for our annual Isenberg endowed lecture, this year from @NobelPrize laureate Dr Harvey Alter!

[Rohit Loomba @DrLoomba]

Loved our ⁦@UCSDHealth⁩ Gastroenterolgy Pickle Ball Event yesterday- great vibe and energy- fellows were gracious winners 🏅 and appreciate our wellness director Selena Kuo!!! ⁦@AmerGastroAssn⁩ ⁦@AmCollegeGastro⁩ ⁦@aasld_org⁩ ⁦@UCSDChangLab⁩